Dr. Choyke on Which Patients Benefit From Active Surveillance in Prostate Cancer

Peter Choyke, MD, FACR
Published: Thursday, Aug 03, 2017



Peter Choyke, MD, FACR, chief of Molecular Imagine Program, National Cancer Institute, discusses which patients with prostate cancer benefit from active surveillance.

There is very good long-term safety data for patients who are appropriately selected for active surveillance, says Choyke.

The patients who benefit from active surveillance have very low-risk cancer with a negative MRI.
 


Peter Choyke, MD, FACR, chief of Molecular Imagine Program, National Cancer Institute, discusses which patients with prostate cancer benefit from active surveillance.

There is very good long-term safety data for patients who are appropriately selected for active surveillance, says Choyke.

The patients who benefit from active surveillance have very low-risk cancer with a negative MRI.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x